GPP
RARE icon

Great Point Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Great Point Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300,000
Closed -$6.9M – 46
2025
Q4 		$6.9M Buy
+300,000
New +$9.87M 2.24% 18
2024
Q1 		– Sell
-648,000
Closed -$31M – 40
2023
Q4 		$31M Sell
648,000
-79,426
-11% -$3.08M 5.28% 5
2023
Q3 		$25.9M Buy
727,426
+50,000
+7% +$1.98M 4.72% 5
2023
Q2 		$31.2M Hold
677,426
– – 6.12% 2
2023
Q1 		$27.2M Buy
677,426
+335,126
+98% +$14.4M 5.33% 4
2022
Q4 		$15.9M Buy
+342,300
New +$13.5M 3.11% 13

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Great Point Partners's RARE Position: Q1 2026 in Review

Great Point Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 300,000 shares — an estimated $6.9M sold.

Great Point Partners first reported a position in RARE in Q4 2022 and held it in 6 quarters. The position peaked at $31.2M in Q2 2023. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Great Point Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Great Point Partners sold 300,000 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.9M.
  • Great Point Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 6 quarters.
  • Great Point Partners's Ultragenyx Pharmaceutical position peaked at $31.2M in Q2 2023.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.